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1. Introduction 
Fibronectin is a high-M r glycoprotein which is 
found in the blood plasma nd other body fluids, in 
connective tissues and in basement membrane [ 1-7]. 
Fibronectin is involved in a variety of cell functions - 
adhesion on different surfaces, cell motility, phago- 
cytosis [1-7]. Fibronectin is a multidomain disulfide- 
bonded imer, the dimensions of the molecule are 
15 X 8 nm;/3-form is the main element of secondary 
structure [8,9]. Fibronectin has an affinity to the cell 
surface, collagen, heparin, fibrinogen, DNA, actin and 
some other macromolecules [1-7]. Similar chemical 
properties and functions are characteristic for fibro- 
nectins isolated from different sources. Moreover, 
conventional ntibodies generated against one of the 
types of this protein usually exhibit significant cross 
reactivity with fibronectins of the other origin [10,11 ]. 
The immunologic similarity of fibronectins can be 
illustrated by the fact that antibodies against human 
plasma fibronectin cross-react with the homologous 
protein from sponges [12]. However, monoclonal nti- 
bodies have been obtained which distinguish between 
different forms of this protein [13-15], thus demon- 
strating the difference between plasma nd cellular 
fibronectin [ 13]. In [ 14,15] monoclonal ntibodies 
specifically recognizing fibronectin from amniotic 
fluid were described. Monoclonal antibody recognizing 
a single antigenic determinant can provide a sharp 
experimental tool for the conformational and func- 
tional analysis of large multidomain proteins. For 
example, monoclonal ntibodies were very useful in 
the localization and isolation of the ceil adhesion frag- 
ment and the site of structural difference between 
cellular and plasma forms of fibronectin [ 13,14]. 
We describe here species-specific monoclonal nti- 
bodies ensitive to the conformational transitions of 
the fibronectin molecule. We have also localized the 
antibody-binding site, i.e., the antigenic determinant 
specific for human and rhesus macaque plasma fibro- 
nectin. 
2. Materials and methods 
Fibronectin was isolated from human plasma by 
affinity chromatography on gelatin-Sepharose fol- 
lowed by ion-exchange chromatography on Whatman 
DE-52 cellulose [16]. The characteristics of our 
human plasma fibronectin preparation have been pub- 
lished [9]. Fibronectins from pig, rat, calf, chicken 
and rhesus macaque plasma were isolated by affinity 
chromatography on gelatin-Sepharose and concen- 
trated by ammonium sulfate precipitation (40% satu- 
ration). 
Hybridomas secreting antibodies specific for fibro- 
nectin were prepared by the general method in [17]. 
BALB/c mice were immunized with intravenous 
injections of fibronectin (100/ag), followed by 
booster injections of the same amount of protein 
after 45 days. After 4 days the spleens were excised, 
and the spleen cells were fused with mouse myeloma 
cells P3/NSI-1-Ag 4-1. After growth on a selective 
medium containing hypoxanthine, aminopterin and 
thymidine the hybrid cells were seeded into 24-weU 
plates (Lindbro, Flow Labs). Positive clones secreting 
antifibronectin antibodies were detected by a solid- 
phase radioimmunoassay; these were then subcloned 
by limiting dilution and expanded as ascites tumors in 
BALB/c mice. The antibodies were precipitated from 
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ascites fluid with sodium sulfate (18% saturation), 
dissolved in the 0.2 M Na3BO3, 0.15 M NaC1 (pH 8.0) 
and dialyzed against he same buffer. The clone used 
in this work was marked 2F. Antibodies ynthesized 
by this cell line belong to the class IgG1, ~. Conven- 
tional antifibronectin antibodies were affinity-purified 
in fibronectin-Sepharose. 
Fibronectin-antibody interaction was tested by 
enzyme-linked immunoassay (ELISA) [ 18]. Poly- 
sterene 96-well microtiter plates (Falcon) were incu- 
bated overnight at 4°C with a solution of fibronectin 
in sodium carbonate buffer. To test the effect of heat 
denaturation on fibronectin-antibody interaction, 
fibronectin was heated for 5 rain prior to coating the 
plate and immediately cooled to 4°C. The unbound 
antigen was removed by washing with phosphate- 
buffered saline, containing 0.05% Tween 20. Mono- 
clonal or conventional ntifibronectin antibodies 
were allowed to interact with fibronectin for 1 h at 
20°C. Goat (anti-rabbit IgG) IgG and rabbit (anti- 
mouse IgG) IgG containing conjugated horseradish 
peroxidase were used as a second layer for detecting 
conventional nd monoclonal antibodies, respectively. 
To isolate short fibronectin fragments, the protein 
(3 mg/ml) was cleaved by trypsin (30 #g/ml) in 
0.02 M Tris-HCl (pH 7.4), 4 M urea at 20°C for 6 h 
[19]. Trypsin was added in two portions with a 3-h 
interval [19]. The electrophoretic analysis did not 
reveal the peptides ofM r > 30 000. Monoclonal anti- 
body-binding fragments were isolated by affinity 
chromatography onmonoctonal ntibody-Sepharose 
(1 mg IgG/ml gel). 
3. Results and discussion' 
Fibronectin is a strong antigen and antifibronectin 
antibodies are known to exhibit the significant cross 
reactivity with fibronectins from different sources 
[10,11]. The data shown in fig.1 demonstrate he 
ability of conventional nti-human plasma fibronectin 
antibodies to interact with fibronectins from differ- 
ent biological species. These antibodies practically do 
not distinguish between human, pig, rat and rhesus 
macaque plasma fibronectins, while their affinity to 
the homologous protein from calf and chicken plasma 
though somewhat lower, is still high. Thus, we have 
obtained monoclonal ntibodies against human plasma 
fibronectin which exhibit a certain species pecificity. 
These antibodies recognize fibronectins from human 
and rhesus macaque plasma, but do not interact with 
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Fig.1. Interaction of conventional ntibodies against human 
plasma fibronectin with fibronectins , obtained from plasma 
of different species; 100% = the plateau level in the reaction 
of antibodies with human-plasma fibronectin; antibodies 
were 3 t~g/ml; (t3) human fibronectin; (zx) pig fibronectin; (o) 
rat fibronectin, (e) rhesus macaque fibronectin; (A) calf fibro- 
nectin; (=) chicken fibronectin; (e) non-immune rabbit IgG 
instead of antifibronectin a tibodies. 
rat, calf, pig and chicken plasma fibronectins (fig.2). 
Thus, in spite of the chemical similarity of fibronec- 
tins from different biological species, monoclonal 
antibodies reveal the antigenic determinant which is 
shared by human and rhesus macaque plasma fibro- 
nectins, but is absent in the homologous proteins 
from rat, pig, calf and chicken plasma. 
To isolate short monoclonal antibody-binding frag- 
ments of fibronectin, trypsin digestion in the pres- 
ence of 4 M urea was carried out. Cleavage products, 
containing peptides with M r < 30 000 were adsorbed 
on monoclonal antibody-Sepharose. The retained 
fraction was eluted and analyzed. The absorption was 
shown to be specific as the fragments were able to 
interact with monoclonal antibody again (fig.2A). 
Eluted fragments were found to be ofM r 25 000-  
27 000 by SDS-polyacrylamide g l electrophoresis 
(fig.2). Thus, the antigenic determinant which is rec- 
ognized by monoclonal antibody in this investigation 
does not exceed 10% of the fibronectin monomer 
polypeptide chain. The fibronectin molecule contains 
several structural domains which are resistant to pro- 
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Fig.2. Interaction of monoclonal ntibodies against human-plasma fibronectin with fibronectins obtained from plasma of differ- 
ent species; 100% = the plateau level in the reaction of antibodies with human plasma fibronectin; antibodies were 12 ug/ml; (A) 
1, human fibronectin; 2, the tryptic fragments retained on monoclonal ntibodies-Sepharose (el ctrophoregram in the left upper 
corner); 3, calf fibronectin; 4,chicken fibronectin; 5, instead of monoclonal ntibodies non-immune mouse IgG were added; (B) 
1, human fibronectin; 2, rhesus macaque fibronectin; 3, rat fibronectin; 4, pig fibronectin. 
10 
clonal antibody-binding site is a part of the structural 
domains we studied the effect of heat and pH-dena- 
turation on the ability of fibronectin to interact with 
monoclonal antibodies. The antigenic determinant 
was not disturbed by heating of the protein to 60°C 
or by a weak alkaline pH (fig.3). Heating to 70°C and 
80°C causes the loss of  the affinity of monoclonal 
antibodies to denatured fibronectin. These data are in 
good agreement with the results of spectroscopic, al- 
orimetric, electron microscopic and sedimentational 
studies of fibronectin, as well as with conformational 
analysis of the protein with conventional ntibodies 
[8,9,22]. In [9] heat denaturation of the fibronectin 
molecule occurred in several steps and began at ~60°C 
Fig.3. Effect of heating and alkaline pH on monoclonal nti- 
bodies-fibronectin interaction; antibodies were 0.2 ~g/ml; 
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Fig.4. Model of the fibronectin monomer showing the posi- 
tion of biologically active tryptic fragments according to 
[21]; (~)  monoclonal ntibody-binding site (A); K, 
M r X 10 -a. 
[9]. However, at alkaline pH the protein molecule 
undergoes unfolding which is not accompanied by the 
disruption of the domains [8]. Thus, the monoclonal 
antibody-binding fragment of the fibronectin mole- 
cule seems to be a structural domain or at least a part 
of  one. 
To define the position of our monoclonal anti- 
body-binding fragment on the fibronectin molecule 
we obtained a tryptic 200 000-190 000 M r fragment 
that contains both heparin- and gelatin-binding sites, 
70 000 M r gelatin- and 70 000 M r heparin-binding 
fragments. These fragments are known to be localized 
close to two terminals of the molecule (fig.4). The 
70 000 M r gelatin- and heparin-binding fragments do 
not interact with the monoclonal antibody. However, 
a large 200 000-190 000 M r fragment, that contains 
both gelatin- and heparin-binding sites, interacts with 
our monoclonal antibody. These results uggest that 
the monoclonal antibody-binding site is located in the 
central part of  the polypeptide chain (fig.4). 
Thus, anti-human plasma fibronectin monoclonal 
antibodies, possessing a certain species pecificity, 
interact with a 25 000-27  000 M r structural domain 
of the fibronectin moleeule, located in the central 
part of the protein polypeptide chain. 
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